Mirko Farina, Marco Chiarini, Camillo Almici, Eugenia Accorsi Buttini, Francesco Zuccalà, Simone Piva, Irene Volonghi, Loris Poli, Simona Bernardi, Federica Colnaghi, Federica Re, Alessandro Leoni, Nicola Polverelli, Alessandro Turra, Enrico Morello, Anna Galvagni, Daniele Moratto, Duilio Brugnoni, Chiara Cattaneo, Emilio Ferrari, Andrea Bianchetti, Michele Malagola, Alessandro Re, Domenico Russo
The development of chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of hematological diseases. However, approximately 60% of patients relapse after CAR-T cell therapy, and no clear cause for this failure has been identified. The objective of the Bio-CAR-T BS study (ClinicalTrials.gov: NCT05366569) is to improve our understanding of the lymphocyte harvest to maximize the quality of the CAR-T cell product. Of the 14 patients enrolled, 11 were diagnosed with DLBCL, 2 with PMBCL, and 1 with ALL...
October 27, 2022: Cancers